McKesson Corporation · NYSE:MCK

McKesson — REMS Program Companies (RPC) — 2014 CE Provider Information Webinar

19 slides from McKesson's conference presentation, Mar 27, 2014

  1. Slide 1: REMS Program Companies (RPC) 2014 CE Provider Information Webinar

    REMS Program Companies (RPC) 2014 CE Provider Information Webinar March 27, 2014 -1- Copyright © 2014 Campbell Alliance, Ltd. All Rights Reserved. Copyright © 2014 Campbell Alliance, Ltd. All Rights Reserved. Confidential and Proprietary. Confidential and Proprietary.

  2. Slide 2: Housekeeping

    2014 Provider Information Webinar Housekeeping Before We Begin…  Participants are asked to mute their lines when they are not speaking  During the presentation, please submit questions through the WebEx via chat function to “Stephanie Cordato”  Questions submitted in advance and through WebEx wil

  3. Slide 3: Agenda

    2014 Provider Information Webinar Agenda REMS Provider Information Webinar Agenda Item Facilitator Introductions and Welcome Campbell Alliance REMS Compliant CE: 2014 RFA CE Subteam Introduction to the REMS CE and the RPC Linda Kitlinski CE Subteam REMS Primary Target Audience Overview Linda Kitlins

  4. Slide 4: Introductions – RPC Continuing Education Subteam

    2014 Provider Information Webinar Introductions – RPC Continuing Education Subteam The Continuing Education (CE) Subteam is the group within RPC that is responsible for all CE-related aspects of the REMS. The CE Subteam are the primary authors of the 2014 CE RFA and also serve as the RPC Educational

  5. Slide 5: Introduction to the REMS CE and the RPC

    2014 Provider Information Webinar Introduction to the REMS CE and the RPC The purpose of the ER/LA Opioid Analgesics REMS is to ensure that the benefits of ER/LA opioid analgesics outweigh the risks in patients whose clinicians have determined these medications to be an appropriate treatment option.

  6. Slide 6: Introduction to the REMS CE and the RPC (continued)

    2014 Provider Information Webinar Introduction to the REMS CE and the RPC (continued) The recent Conjoint Committee on Continuing Education (CCCE) REMS Meeting held on February 24 exemplifies the collaborative efforts of the CE Community, FDA and RPC to address this important public health/patient s

  7. Slide 7: REMS CE Primary Target Audience Overview

    2014 Provider Information Webinar REMS CE Primary Target Audience Overview The FDA REMS defines the primary audience for REMS-compliant CE as those clinicians who are actively prescribing ER/LA opioid analgesics. Primary Audience for REMS-compliant CE  The ER/LA Opioid REMS CE education/training go

  8. Slide 8: REMS CE Primary Target Audience Overview (continued)

    2014 Provider Information Webinar REMS CE Primary Target Audience Overview (continued) The FDA REMS defines the primary audience for REMS-compliant CE as those clinicians who are actively prescribing ER/LA opioid analgesics. Appendix B of the 2014 RFA provides demographic information about this prim

  9. Slide 9: REMS CE Primary Target Audience Overview (continued)

    2014 Provider Information Webinar REMS CE Primary Target Audience Overview (continued) The FDA REMS defines the primary audience for REMS-compliant CE as those clinicians who are actively prescribing ER/LA opioid analgesics. Appendix B of the 2014 RFA provides demographic information about this prim

  10. Slide 10: REMS CE Primary Target Audience Overview (continued)

    2014 Provider Information Webinar REMS CE Primary Target Audience Overview (continued) Given the importance of the REMS to patient safety and public health, other health care professionals are also strongly encouraged to participate in REMS-compliant CE.  While the primary audience for REMS CE defi

  11. Slide 11: REMS-Compliant CE Requirements

    2014 Provider Information Webinar REMS-Compliant CE Requirements REMS-compliant CE requirements are specifically defined by the FDA and all RPC-supported CE activities must adhere to all of these requirements. Requirements for REMS-Compliant CE  “REMS-compliant CE” must:  Include ALL elements of F

  12. Slide 12: Overview of the 2014 CE RFA – Sections 1-5

    2014 Provider Information Webinar Overview of the 2014 CE RFA – Sections 1-5 The 2014 RFA places a strong emphasis on organization and demonstration of REMS-compliance while incorporating innovative learning elements. 1 Scope of Problem and  General information around chronic pain in the US and pot

  13. Slide 13: Grant Request Evaluation Criteria: Overview

    2014 Provider Information Webinar Grant Request Evaluation Criteria: Overview While all RPC-supported CE must be REMS compliant and will be evaluated based on all criteria outlined in the 2014 CE RFA, there are several criteria that are especially important for Providers to consider. Key Grant Evalu

  14. Slide 14: Grant Request Evaluation Criteria: Timeline for Evaluation

    2014 Provider Information Webinar Grant Request Evaluation Criteria: Timeline for Evaluation The submission date for all grant proposals in response to the 2014 CE RFA is Wednesday, April 30 at 5:00pm ET. The CE Subteam and the RPC will evaluate proposals and anticipate final decisions being made in

  15. Slide 15: Summary of Key RFA Information

    2014 Provider Information Webinar Summary of Key RFA Information Grant Request Information  The 2014 CE RFA is accessible on the RPC CE Website: http://ce.er-la-opioidrems.com  The RPC Grant Management System will be accepting applications until 5:00pm ET on Wednesday, April 30th  If you have not

  16. Slide 16: Review of Questions (Slide 1 of 4)

    2014 Provider Information Webinar Review of Questions (Slide 1 of 4) The following questions were received for the Provider Information Webinar on March 27, 2014. Question Response What are the key differences between Differences in the 2014 RFA include: the 2013 RFA and the 2014 RFA?  Applicant el

  17. Slide 17: Review of Questions (Slide 2 of 4)

    2014 Provider Information Webinar Review of Questions (Slide 2 of 4) The following questions were received for the Provider Information Webinar on March 27, 2014. Question Response We noticed that in the past, the As the February 28, 2015 date nears for achieving the first FDA REMS goal submission d

  18. Slide 18: Review of Questions (Slide 3 of 4)

    2014 Provider Information Webinar Review of Questions (Slide 3 of 4) The following questions were received for the Provider Information Webinar on March 27, 2014. Question Response Is there a cost per learner range? While there is no cost per learner range specified in the RFA, Providers should bear

  19. Slide 19: Review of Questions (Slide 4 of 4)

    2014 Provider Information Webinar Review of Questions (Slide 4 of 4) The following questions were received for the Provider Information Webinar on March 27, 2014. Question Response Is there a preference on whether the RPC ‘s goal is to support a range of programs which enable learners to programs ar

REMS Program Companies (RPC) — 2014 CE Provider Information Webinar on 6ix